$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio

$pbio Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224023201 Filed on June 07, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue		$312.4K	$1.978M
YoY Change		-48.56%	14.38%
Cost Of Revenue		$333.5K	$1.178M
YoY Change		-73.77%	-41.5%
Gross Profit		-$21.17K	$799.8K
YoY Change		-96.81%	-380.97%
Gross Profit Margin		-6.78%	40.43%
Selling, General & Admin		$3.107M	$8.936M
YoY Change		393.21%	145.21%
% of Gross Profit			1117.25%
Research & Development		$362.7K	$1.367M
YoY Change		43.45%	41.01%
% of Gross Profit			170.94%
Depreciation & Amortization		$28.11K	$25.92K
YoY Change		-45.73%	-22.06%
% of Gross Profit			3.24%
Operating Expenses		$3.470M	$10.30M
YoY Change		293.05%	123.31%
Operating Profit		-$3.491M	-$9.503M
YoY Change		125.68%	94.01%
Interest Expense		-$1.485M	$15.58M
YoY Change		-62.66%	49.27%
% of Operating Profit
Other Income/Expense, Net		-$268.6K	-$19.81M
YoY Change		-3169.49%	77.23%
Pretax Income		-$9.904M	-$29.31M
YoY Change		122.14%	82.34%
Income Tax
% Of Pretax Income
Net Earnings		-$10.54M	-$29.31M
YoY Change		115.45%	82.34%
Net Earnings / Revenue		-3373.1%	-1482.02%
Basic Earnings Per Share			-$1.51
Diluted Earnings Per Share		-$0.33	-$1.51
COMMON SHARES
Basic Shares Outstanding	34.71M shares	21.73M shares	23.34M shares
Diluted Shares Outstanding			23.34M shares

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$81.28K	$81.28K
YoY Change	2000.26%	2000.26%
Cash & Equivalents	$81.28K	$81.28K
Short-Term Investments
Other Short-Term Assets	$222.6K	$222.6K
YoY Change	-13.55%	-13.55%
Inventory	$304.9K	$304.9K
Prepaid Expenses
Receivables	$151.2K	$151.2K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$760.1K	$760.1K
YoY Change	-38.86%	-38.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$84.93K	$227.8K
YoY Change	-17.82%	-40.91%
Goodwill
YoY Change
Intangibles	$0.00
YoY Change	-100.0%
Long-Term Investments	$61.88K	$61.88K
YoY Change	-2.77%	-2.77%
Other Assets
YoY Change
Total Long-Term Assets	$289.6K	$289.6K
YoY Change	-62.21%	-62.21%
TOTAL ASSETS
Total Short-Term Assets	$760.1K	$760.1K
Total Long-Term Assets	$289.6K	$289.6K
Total Assets	$1.050M	$1.050M
YoY Change	-47.77%	-47.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.320M	$1.320M
YoY Change	107.21%	107.21%
Accrued Expenses	$3.119M	$3.119M
YoY Change	11.11%	11.11%
Deferred Revenue
YoY Change
Short-Term Debt	$22.60M	$22.60M
YoY Change	12.43%	12.43%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$33.58M	$33.58M
YoY Change	-2.41%	-2.41%
LONG-TERM LIABILITIES
Long-Term Debt	$161.9K	$161.9K
YoY Change	7.91%	7.91%
Other Long-Term Liabilities	$65.52K	$65.52K
YoY Change	-53.78%	-53.78%
Total Long-Term Liabilities	$227.4K	$227.4K
YoY Change	-22.06%	-22.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$33.58M	$33.58M
Total Long-Term Liabilities	$227.4K	$227.4K
Total Liabilities	$33.80M	$33.80M
YoY Change	-2.57%	-2.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$169.0M
YoY Change	26.3%
Common Stock	$353.7K
YoY Change	158.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$32.75M	-$32.75M
YoY Change
Total Liabilities & Shareholders Equity	$1.050M	$1.050M
YoY Change	-47.77%	-47.77%

Cashflow Statement

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$10.54M	-$29.31M
YoY Change	115.45%	82.34%
Depreciation, Depletion And Amortization	$28.11K	$25.92K
YoY Change	-45.73%	-22.06%
Cash From Operating Activities	-$1.132M	-$3.186M
YoY Change	-20.65%	-28.85%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$7.495K
YoY Change	-100.0%	-63.89%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$7.495K
YoY Change	-100.0%	-63.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$150.0K
YoY Change		500.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.208M	$3.271M
YoY Change	0.7%	-25.16%
NET CHANGE
Cash From Operating Activities	-1.132M	-$3.186M
Cash From Investing Activities	0.000	-$7.495K
Cash From Financing Activities	1.208M	$3.271M
Net Change In Cash	76.01K	$77.41K
YoY Change	-133.48%	-160.27%
FREE CASH FLOW
Cash From Operating Activities	-$1.132M	-$3.186M
Capital Expenditures	$0.00	$7.495K
Free Cash Flow	-$1.132M	-$3.194M
YoY Change	-20.65%	-29.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000830656
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2022Q4	PBIO	Convertible Preferred Stock Liability ConvertiblePreferredStockLiability		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	PBIO	Deemed Dividends On Extension Of Warrants DeemedDividendsOnExtensionOfWarrants		usd
CY2022	PBIO	Stock Issued During Period Value Conversion Of Convertible Securities Conversion Of Preferred Stock For Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock		usd
CY2023	PBIO	Steries Aa Preferred Stock Warrant Extension SteriesAaPreferredStockWarrantExtension		usd
CY2023	PBIO	Stock Issued During Period Value Conversion Of Convertible Securities Conversion Of Preferred Stock For Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock		usd
CY2023	PBIO	Conversion Of Common Stock To Preferred Stock ConversionOfCommonStockToPreferredStock		usd
CY2022	PBIO	Issuance Of Preferred Stock For Dividends Paidinkind IssuanceOfPreferredStockForDividendsPaidinkind		usd
CY2022	PBIO	Issuance Of Preferred Stock For Services IssuanceOfPreferredStockForServices		usd
CY2022	PBIO	Preferred Stock Issued For Debt Extension PreferredStockIssuedForDebtExtension		usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment		usd
CY2023	PBIO	Early Asu202006 Adoption EarlyAsu202006Adoption		usd
CY2022	PBIO	Conversion Of Common Stock For Preferred Stock ConversionOfCommonStockForPreferredStock		usd
CY2022	PBIO	Preferred Stock Issued With Debt PreferredStockIssuedWithDebt		usd
CY2022	PBIO	Preferred Shares Liability PreferredSharesLiability		usd
CY2023	PBIO	Discount From Warrants Issued With Debt DiscountFromWarrantsIssuedWithDebt		usd
CY2022	PBIO	Conversion Of Nonconvertible Debt To Convertible ConversionOfNonconvertibleDebtToConvertible		usd
CY2022	PBIO	Conversion Of Debt Interest Preferred Stock Dividend For Preferred Stock ConversionOfDebtInterestPreferredStockDividendForPreferredStock		usd
CY2022	PBIO	Extension Of Warrants For Series Aa Preferred Stock ExtensionOfWarrantsForSeriesAaPreferredStock		usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment		usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Options Non Option Equity Instruments Grants In Period Gross Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOptionEquityInstrumentsGrantsInPeriodGrossExercisable		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2022	PBIO	Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Options Non Option Equity Instruments Grants In Period Gross Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOptionEquityInstrumentsGrantsInPeriodGrossExercisable		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023	PBIO	Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2023	PBIO	Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeituresInPeriodWeightedAverageExercisePrice
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Canton
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02021
CY2023	dei	City Area Code CityAreaCode	(508)
CY2023	dei	Local Phone Number LocalPhoneNumber	230-1828
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	8002541	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34710509	shares
CY2023	dei	Auditor Firm AuditorFirmId	206
CY2023	dei	Auditor Name AuditorName	MaloneBailey, LLP
CY2023	dei	Auditor Location AuditorLocation	Houston, Texas
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81279	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3865	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	151234	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	295374	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1021812	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	982973	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	304909	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	686383	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	222633	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	257527	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	760055	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1243149	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	61876	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	63638	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84930	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	103351	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	142815	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	282095	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	317308	usd
CY2023Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	1264162	usd
CY2022Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	1638969	usd
CY2023Q4	PBIO	Convertible Preferred Stock Liability ConvertiblePreferredStockLiability	1000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	33576120	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34404166	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	161864	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	60961	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	139924	usd
CY2023	PBIO	Deemed Dividends On Extension Of Warrants DeemedDividendsOnExtensionOfWarrants	3626950	usd
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	2261186	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1727275	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35202434	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4560	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1822	usd
CY2023Q4	us-gaap	Liabilities Liabilities	33803505	usd
CY2022Q4	us-gaap	Liabilities Liabilities	34695912	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	102	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1098	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35367663	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35367663	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13682910	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13682910	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	353677	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	136829	usd
CY2023Q4	PBIO	Warrants To Acquire Common Stock WarrantsToAcquireCommonStock	35684321	usd
CY2022Q4	PBIO	Warrants To Acquire Common Stock WarrantsToAcquireCommonStock	31995762	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	100236710	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69006145	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-169028639	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133826205	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-32753829	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-32686371	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1049676	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2009541	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1977763	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1729343	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1178201	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2014004	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1367154	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	969532	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	730714	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	401444	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8205052	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3242652	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	11481121	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	6627632	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-9503358	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4898289	usd
CY2023	us-gaap	Interest Expense InterestExpense	15581440	usd
CY2022	us-gaap	Interest Expense InterestExpense	10438565	usd
CY2023	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-1762	usd
CY2022	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	3662	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3970983	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-751335	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-256755	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7849	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19810940	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11178389	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-29314298	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16076678	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17803953	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.51
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.51
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.61
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.61
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23336620	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23336620	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11058356	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11058356	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-22208961	usd
CY2022	PBIO	Cumulative Effect Period Of Adoption Adjustment CumulativeEffectPeriodOfAdoptionAdjustment	-473027	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	215098	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17443	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	1727275	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	392175	usd
CY2022	PBIO	Warrants Issued For Debt Extension WarrantsIssuedForDebtExtension	132537	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2198861	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	467092	usd
CY2022	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	386300	usd
CY2022	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	2943139	usd
CY2022	PBIO	Stock Issued With Debt StockIssuedWithDebt	873854	usd
CY2022	PBIO	Sale Of Common Stock For Cash SaleOfCommonStockForCash	25000	usd
CY2022	PBIO	Warrants Issued For Services WarrantsIssuedForServices	54495	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	93576	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16076678	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-32686371	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-32686371	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	81111	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2636443	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	1726935	usd
CY2023	PBIO	Stock Issued During Period Value Series Cc Stock Dividend StockIssuedDuringPeriodValueSeriesCCStockDividend	534251	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2020935	usd
CY2023	PBIO	Issuance Of Common Stock Warrants For Services IssuanceOfCommonStockWarrantsForServices	61609	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2028748	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	509033	usd
CY2023	PBIO	Stock Issued During Period Value Conversion Of Convertible Preferred Stock Securities StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockSecurities	10017212	usd
CY2023	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	386936	usd
CY2023	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	8226186	usd
CY2023	PBIO	Stock Issued With Debt StockIssuedWithDebt	790975	usd
CY2023	PBIO	Sale Of Common Stock For Cash SaleOfCommonStockForCash	150000	usd
CY2023	PBIO	Issuance Of Preferred Stock For Services IssuanceOfPreferredStockForServices	1360867	usd
CY2023	PBIO	Preferred Stock For Debt Extension PreferredStockForDebtExtension	2674530	usd
CY2023	PBIO	Preferred Stock Issued With Debt PreferredStockIssuedWithDebt	563441	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-29314298	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-32753829	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-29314298	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16076678	usd
CY2023	PBIO	Gain On Loan Forgiveness GainOnLoanForgiveness	1129679	usd
CY2022	PBIO	Gain On Loan Forgiveness GainOnLoanForgiveness	10000	usd
CY2023	PBIO	Noncash Lease Expense Income NoncashLeaseExpenseIncome	139280	usd
CY2022	PBIO	Noncash Lease Expense Income NoncashLeaseExpenseIncome	113470	usd
CY2023	PBIO	Common Stock And Warrants Issued For Interest CommonStockAndWarrantsIssuedForInterest	8226186	usd
CY2022	PBIO	Common Stock And Warrants Issued For Interest CommonStockAndWarrantsIssuedForInterest	2943139	usd
CY2023	PBIO	Issuance Of Preferred Stock For Dividends Paidinkind IssuanceOfPreferredStockForDividendsPaidinkind	602616	usd
CY2023	PBIO	Issuance Of Preferred Stock For Services IssuanceOfPreferredStockForServices	1360867	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	112454	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	119788	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2507055	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1777863	usd
CY2023	PBIO	Common Stock And Warrants Issued For Debt Extension CommonStockAndWarrantsIssuedForDebtExtension	-2028748	usd
CY2022	PBIO	Common Stock And Warrants Issued For Debt Extension CommonStockAndWarrantsIssuedForDebtExtension	-2331398	usd
CY2023	PBIO	Preferred Stock Issued For Debt Extension PreferredStockIssuedForDebtExtension	3071914	usd
CY2023	PBIO	Allowance For Inventory Reserve AllowanceForInventoryReserve	121891	usd
CY2022	PBIO	Allowance For Inventory Reserve AllowanceForInventoryReserve	641815	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2636443	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	215098	usd
CY2023	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	-1762	usd
CY2022	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	3662	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2082544	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	446670	usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	230770	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-144140	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	140628	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-259583	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	180644	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-34894	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-165090	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	683194	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	109314	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	24331	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	49567	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-154239	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-113470	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3143534	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3133829	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3186010	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4478041	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7495	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20755	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7495	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20755	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	150000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	81111	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17443	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5456960	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4907222	usd
CY2023	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	2614761	usd
CY2022	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	2710000	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	181700	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	866350	usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	2742409	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1522494	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	185000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	315300	usd
CY2023	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	2286204	usd
CY2022	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	2317871	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3270919	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4370350	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	77414	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-128446	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3865	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	132311	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	81279	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3865	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1475864	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1378647	usd
CY2022	PBIO	Early Asu202006 Adoption EarlyAsu202006Adoption	473027	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	790975	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	873854	usd
CY2023	PBIO	Conversion Of Preferred Stock For Common Stock ConversionOfPreferredStockForCommonStock	29920	usd
CY2022	PBIO	Conversion Of Preferred Stock For Common Stock ConversionOfPreferredStockForCommonStock	44	usd
CY2023	PBIO	Conversion Of Common Stock For Preferred Stock ConversionOfCommonStockForPreferredStock	6240	usd
CY2023	PBIO	Preferred Stock Issued With Debt PreferredStockIssuedWithDebt	563441	usd
CY2023	PBIO	Preferred Shares Liability PreferredSharesLiability	1000000	usd
CY2022	PBIO	Discount From Warrants Issued With Debt DiscountFromWarrantsIssuedWithDebt	93576	usd
CY2023	PBIO	Common Stock Issued In Lieu Of Cash For Dividend CommonStockIssuedInLieuOfCashForDividend	386936	usd
CY2022	PBIO	Common Stock Issued In Lieu Of Cash For Dividend CommonStockIssuedInLieuOfCashForDividend	386300	usd
CY2023	PBIO	Conversion Of Nonconvertible Debt To Convertible ConversionOfNonconvertibleDebtToConvertible	691500	usd
CY2023	PBIO	Noncash Preferred Stock Dividends NoncashPreferredStockDividends	2261186	usd
CY2022	PBIO	Noncash Preferred Stock Dividends NoncashPreferredStockDividends	1727275	usd
CY2023	PBIO	Conversion Of Debt Interest Preferred Stock Dividend For Preferred Stock ConversionOfDebtInterestPreferredStockDividendForPreferredStock	10017212	usd
CY2023	PBIO	Conversion Of Debt Into Common Stock ConversionOfDebtIntoCommonStock	509033	usd
CY2022	PBIO	Conversion Of Debt Into Common Stock ConversionOfDebtIntoCommonStock	467092	usd
CY2023	PBIO	Extension Of Warrants For Series Aa Preferred Stock ExtensionOfWarrantsForSeriesAaPreferredStock	3626950	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1480769	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1021812	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	982973	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	304909	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	686383	usd
CY2023	us-gaap	Depreciation Depreciation	25916	usd
CY2022	us-gaap	Depreciation Depreciation	33250	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zCSaTGLHIEKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ii. <span id="xdx_862_z125Cb9kXcpf">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1978000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1729000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1729000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1978000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1729000	usd
CY2023Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	151000	usd
CY2022Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	295000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	34000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	60000	usd
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	381627	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	374132	usd
CY2023Q4	PBIO	Extended Warranty Service ExtendedWarrantyService	34000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	63950	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	188587	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1262771	usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	230770	usd
CY2023Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	0	usd
CY2022Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	317308	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zCyf4H38yN77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>xi. <span id="xdx_86C_zUDHtCypmeMk">Concentrations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Credit Risk</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected. At December 31, 2023, we determined that no allowance against accounts receivable was necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--FairValueConcentrationOfRiskTextBlock_zE600W7dQ8Ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zUZMVGDlL6zf" style="display: none">Schedule of Customer Concentration Risk Percentage</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Top Five Customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zS6gtxuh6okk" title="Concentration credit risk percentage">43</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zcTtuu0WZ8Ni" title="Concentration credit risk percentage">24</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Federal Agencies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zV7arcOWVNyk" title="Concentration credit risk percentage">4</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2gzzNZcG3Ta" title="Concentration credit risk percentage">0</span></td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">One customer, our Chinese distributor, accounted for greater than <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zU9J4YGgVm4" title="Concentration risk percentage">10</span>% of the total 2023 revenue recorded.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Top Five Customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zY2PdoekQGF1" title="Concentration credit risk percentage">96</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmtY8ze4E8ig" title="Concentration credit risk percentage">93</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Federal Agencies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfctlUkn266" title="Concentration credit risk percentage">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUE6bkxqbqgb" title="Concentration credit risk percentage">0</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A0_zMc4MNezEzQa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Three customers accounted for greater than <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_zwk0VrhYfuLg" title="Concentration risk percentage">10</span>% of the total accounts receivable balance at December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investment in Equity Securities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, we held <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20231231__dei--LegalEntityAxis__custom--NexityGlobalSAMember_zoql172Rshwd" title="Sale of stock number of shares received"><span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20221231__dei--LegalEntityAxis__custom--NexityGlobalSAMember_zV0NCkacPO16" title="Sale of stock number of shares received">100,250</span></span> shares of common stock of Nexity Global SA, (a Polish publicly traded company). On October 23, 2020 Everest Investments S.A. changed its name to Nexity Global S.A. Nexity is and Everest was listed on the Warsaw Stock Exchange.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We had exchanged <span id="xdx_907_ecustom--NumberOfCommonStockSharesExchangedDuringPeriod_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EverestMember_zTYf3Pbtj0ka" title="Number of common stock shares exchanged during the period">33,334</span> shares of our common stock for the <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EverestMember_zw19ZXbx5DHe" title="Sale of stock number of shares received">100,250</span> shares we had held in Everest (before the Nexity Merger). We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities.” ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs, of our investment in Nexity to be $<span id="xdx_903_eus-gaap--InvestmentOwnedAtFairValue_iI_c20231231__dei--LegalEntityAxis__custom--NexityGlobalSAMember_zIx8bThdKZ2i" title="Investment owned, at fair value">61,876</span>. We recorded $<span id="xdx_909_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231__dei--LegalEntityAxis__custom--NexityGlobalSAMember_zUaGyHhcOx95" title="Unrealized loss">(1,762)</span> as unrealized loss during the year ended December 31, 2023 for changes in market value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs, of our investment in Nexity to be $<span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_iI_c20221231__dei--LegalEntityAxis__custom--NexityGlobalSAMember_zVA7YPG546E3" title="Investment owned, at fair value">63,638</span>. We recorded $<span id="xdx_90D_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__dei--LegalEntityAxis__custom--NexityGlobalSAMember_z0nyIOD9WEc2" title="Unrealized gain">3,662</span> as unrealized gain during the year ended December 31, 2022 for changes in market value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	194999	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	194999	usd
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	25248	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	25248	usd
CY2023Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	53098	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35202434	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17803953	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23336620	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23336620	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11058356	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11058356	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.51
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.51
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.61
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.61
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	54033581	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33647137	shares
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2636443	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	215098	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	53098	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	654972	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	647477	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	570042	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	544126	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84930	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	103351	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2636443	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	215098	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4090508	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	0	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	373532	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y14D
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	15312	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y1M2D
CY2023	us-gaap	Advertising Expense AdvertisingExpense	342	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	487	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	61876	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	63638	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P9Y
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	80000	usd
CY2023	PBIO	Impairment Of Intangible Assets ImpairmentOfIntangibleAssets	230770	usd
CY2022	PBIO	Impairment Of Intangible Assets ImpairmentOfIntangibleAssets	230770	usd
CY2023Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	750000	usd
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	750000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	750000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	432692	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	317308	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	86538	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	86538	usd
CY2023	us-gaap	Pension Contributions PensionContributions	10792	usd
CY2022	us-gaap	Pension Contributions PensionContributions	12777	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	300254	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	268548	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	1170640	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	99362	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	89474	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	15715	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2533983	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	872967	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	167656	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	104609	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	36324508	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31026899	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40586515	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	32388100	usd
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	91016166	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	64393	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	66969	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	51778	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	183140	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	55284	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	127856	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-154239	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-113470	usd
CY2023	PBIO	Debt Default Convertible Conversion Ratio DebtDefaultConvertibleConversionRatio	0.75	pure
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	142815	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	282095	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	66895	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	142171	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	60961	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	139924	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	127856	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	282095	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y11M15D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	124606	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	151239	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	91800	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	91800	usd
CY2023	us-gaap	Lease Cost LeaseCost	216406	usd
CY2022	us-gaap	Lease Cost LeaseCost	243039	usd
CY2023Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	1051000	usd
CY2023	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	2742409	usd
CY2022Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	541313	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1522494	usd
CY2023	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	March, 2020 to December, 2024
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	13000000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	21329312	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	18279186	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	645471	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	455517	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	20683841	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	17823669	usd
CY2023	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.50
CY2023Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023	PBIO	Debt Default Convertible Conversion Ratio DebtDefaultConvertibleConversionRatio	0.75	pure
CY2023	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.50
CY2023Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	2.50
CY2023Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	2.50
CY2023Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023	us-gaap	Debt Instrument Convertible Conversion Price Decrease DebtInstrumentConvertibleConversionPriceDecrease	2.50
CY2023Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	2.50
CY2023Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q4	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	1	usd
CY2023Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q4	PBIO	Percentage Of Price Rate PercentageOfPriceRate	0.10	pure
CY2023Q4	PBIO	Convertible Lesser Per Share ConvertibleLesserPerShare	2.5
CY2023Q4	PBIO	Convertible Lesser Discount Percent ConvertibleLesserDiscountPercent	0.25	pure
CY2023	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.35	pure
CY2023Q4	PBIO	Convertible Lesser Per Share ConvertibleLesserPerShare	2.50
CY2023Q4	PBIO	Convertible Lesser Discount Percent ConvertibleLesserDiscountPercent	0.25	pure
CY2023	us-gaap	Debt Instrument Convertible Threshold Trading Days DebtInstrumentConvertibleThresholdTradingDays	5	integer
CY2023Q4	PBIO	Default Convertible Lesser Price Per Share DefaultConvertibleLesserPricePerShare	2.50
CY2023Q4	PBIO	Debt Instrument Trading Percent DebtInstrumentTradingPercent	0.60	pure
CY2023	us-gaap	Debt Conversion Description DebtConversionDescription	Some notes can be converted at $2.50 through fixed rate expiration dates; thereafter lesser of (1) lowest trading price during the prior 25 days of the note or 65% of the lowest price during the 25 days prior to the conversion. Notes can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold by PBI at a price lower than $2.50/share. Notes can be voluntary converted at lower of lower of (i) $2.5/share and (ii) purchase Price of stock sold by PBIO at a price lower than $2.50/share that is not an Excluded Event in the Series AA Deal Documents. Notes can be converted at lower of lower of (i) $2.50 or (ii) the conversion price of the Series AA Preferred Stock as adjusted. Notes can be converted at lower of (i) $2.50 or (ii) the purchase price of stock by Series AA Holders. Notes can be voluntary converted at offering price of Common Stock at the close of the day prior to the Conversion Date
CY2023	us-gaap	Debt Instrument Increase Decrease For Period Net DebtInstrumentIncreaseDecreaseForPeriodNet	5625648	usd
CY2023	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	302484	usd
CY2023Q4	us-gaap	Other Borrowings OtherBorrowings	1426026	usd
CY2022Q4	us-gaap	Other Borrowings OtherBorrowings	1788969	usd
CY2023Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	161864	usd
CY2022Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	150000	usd
CY2023Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1264162	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1638969	usd
CY2023	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-05-02
CY2022Q4	us-gaap	Notes Payable NotesPayable	150000	usd
CY2022Q4	PBIO	Accrued Interest Rate Percent AccruedInterestRatePercent	0.0375	pure
CY2022	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	731	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	102	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1098	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1333101	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.72
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16207108	shares
CY2021Q4	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.50
CY2021Q4	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Options And Non Option Equity Instrument Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentOutstandingNumber	17540209	shares
CY2021Q4	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Options And Non Option Equity Instrument Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentExercisableNumber	17308567	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	277500	shares
CY2022	PBIO	Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	3.50
CY2022	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Options Non Option Equity Instruments Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOptionEquityInstrumentsGrantsInPeriodGross	277500	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	25279	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.69
CY2022	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Options Non Option Equity Instruments Exercised In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOptionEquityInstrumentsExercisedInPeriodGross	-25279	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	205839	shares
CY2022	PBIO	Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice	3.50
CY2022	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Options Non Option Equity Instruments Expiration In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOptionEquityInstrumentsExpirationInPeriodGross	-205839	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1307822	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.72
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16278769	shares
CY2022Q4	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.50
CY2022Q4	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Options And Non Option Equity Instrument Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentOutstandingNumber	17586591	shares
CY2022Q4	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Options And Non Option Equity Instrument Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentExercisableNumber	17570591	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7151238	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.25
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	100000	shares
CY2023	PBIO	Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	3.50
CY2023	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Options Non Option Equity Instruments Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOptionEquityInstrumentsGrantsInPeriodGross	7251238	shares
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	117552	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.69
CY2023	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Options Non Option Equity Instruments Exercised In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOptionEquityInstrumentsExercisedInPeriodGross	-117552	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	801415	shares
CY2023	PBIO	Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice	3.50
CY2023	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Options Non Option Equity Instruments Expiration In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOptionEquityInstrumentsExpirationInPeriodGross	-645829	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3420754	shares
CY2023	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Options Non Option Equity Instruments Forfeitures In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOptionEquityInstrumentsForfeituresInPeriodGross	-3420754	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4920754	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.25
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	15577354	shares
CY2023Q4	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.50
CY2023Q4	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Options And Non Option Equity Instrument Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentOutstandingNumber	20628305	shares
CY2023Q4	PBIO	Share Based Compensation Arrangement By Share Based Payment Award Options And Non Option Equity Instrument Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentExercisableNumber	18625326	shares
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	4920754	shares
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P8Y6M
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.25
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	3047972	shares
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P7Y9M18D
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.25
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	117552	shares
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	81111	usd
CY2023	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	2150000	shares
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2082544	usd
CY2023	PBIO	Stock Issued During Period Shares Issued For Debt Extensions StockIssuedDuringPeriodSharesIssuedForDebtExtensions	2552300	shares
CY2023	PBIO	Stock Issued During Period Value Issued For Debt Extensions StockIssuedDuringPeriodValueIssuedForDebtExtensions	2028748	usd
CY2023	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	203613	shares
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	509033	usd
CY2023	PBIO	Stock Issued During Period Value Interest Paid In Kind StockIssuedDuringPeriodValueInterestPaidInKind	8226186	usd
CY2023	PBIO	Stock Issued During Period Shares Issued For Debt StockIssuedDuringPeriodSharesIssuedForDebt	1625642	shares
CY2023	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	790975	usd
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	60000	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	25279	shares
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17443	usd
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	255500	shares
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	392175	usd
CY2022	PBIO	Stock Issued During Period Shares Issued For Debt Extensions StockIssuedDuringPeriodSharesIssuedForDebtExtensions	1423800	shares
CY2022	PBIO	Stock Issued During Period Value Issued For Debt Extensions StockIssuedDuringPeriodValueIssuedForDebtExtensions	2198861	usd
CY2022	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	181918	shares
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	467092	usd
CY2022	PBIO	Stock Issued During Period Shares Conversion Of Preferred Stock StockIssuedDuringPeriodSharesConversionOfPreferredStock	4400	shares
CY2022	PBIO	Stock Issued During Period Value Interest Paid In Kind StockIssuedDuringPeriodValueInterestPaidInKind	2943139	usd
CY2022	PBIO	Stock Issued During Period Shares Issued For Debt StockIssuedDuringPeriodSharesIssuedForDebt	659000	shares
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	873854	usd
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10000	shares
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	5300000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	2700000	usd
CY2020Q4	us-gaap	Debt Instrument Description DebtInstrumentDescription	we are obligated to issue 100,000 warrants if the loan is not repaid before January 23, 2021 and an additional 10,000 shares of common stock and 100,000 warrants if the loan is not repaid before February 23, 2021. We are also obligated to issue 10,000 shares of common stock and 200,000 warrants if the loan is not repaid before March 23, 2021. During the year ended December 31, 2021 the Company issued 400,000 warrants to this lender ($3.50 exercise price and five-year term) with a fair value of $600,298. The Company is also obligated to issue 10,000 shares of common stock to this lender every 31 days up to the loan’s maturity date on June 23, 2021

Files In Submission

Name	View Source	Status
0001493152-24-023201-index-headers.html	Edgar Link	pending
0001493152-24-023201-index.html	Edgar Link	pending
0001493152-24-023201.txt	Edgar Link	pending
0001493152-24-023201-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbio-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pbio-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
pbio-20231231_def.xml	Edgar Link	unprocessable
pbio-20231231_lab.xml	Edgar Link	unprocessable
pbio-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio

2024 Q2 Form 10-K Financial Statement

#000149315224023201 Filed on June 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBIO PRESSURE BIOSCIENCES INC Stock $pbio

2024 Q2 Form 10-K Financial Statement

#000149315224023201 Filed on June 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio